SEC Filing Summary

Robert W. Postma, director at Alaunos Therapeutics, Inc., acquired 8,463 shares of common stock on July 23, 2026, for $1.92 per share. This transaction was in lieu of board fees. Following this acquisition, Postma directly holds 58,609 shares. Additionally, he has indirect ownership of 24 shares through his spouse's IRA and 62,416 shares through WaterMill Asset Management Corp., where he serves as principal. The filing is a Form 4, indicating a change in beneficial ownership.